explore -WSS

explore

author：entertainment 2025-09-28 01:39:24 - browse：492

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Most antidepressants don't work on kids, teens, study finds

WSS

Cholera vaccine supplies dangerously low, outbreaks surging

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Most antidepressants don't work on kids, teens, study finds

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

entertainment

Cancer drug shortages should be causing more outrage

Cholera vaccine supplies dangerously low, outbreaks surging

Psychedelics group wrestles with new pharma identity

Brain MRIs reveal impact of 'toxic stress' on Black children

Walensky prepares to leave CDC — and Congress — behind

NEJM study measures Covid brain fog, impact on IQ

State Dept. review finds Biden bears some blame for Afghanistan failures

Pfizer is about to make a big push in cancer. Will investors listen?

Apple is now the first public company to be valued at $3 trillion

Pfizer is about to make a big push in cancer. Will investors listen?

Wikipedia

Warren pushes Witty on UnitedHealth's control over physicians

Welsh Carson private equity firm escapes from FTC antitrust case

Change Healthcare cyberattack shows risk of industry consolidation

HHS's proposed rule does nothing to address the climate crisis

Children’s Hospital revives plan for pedestrian bridge

HHS's proposed rule does nothing to address the climate crisis

hotspot

explore

hotspot

focus